➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Mallinckrodt
Express Scripts
Baxter

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,906,962

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,906,962 protect, and when does it expire?

Patent 8,906,962 protects LATISSE and is included in one NDA.

This patent has eighteen patent family members in nine countries.

Summary for Patent: 8,906,962
Title:Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
Inventor(s): deLong; Mitchell A. (Chapel Hill, NC), McIver; John M. (Cincinnati, OH), Youngquist; Robert S. (Mason, OH)
Assignee: Duke University (Durham, NC)
Application Number:14/034,372
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,906,962
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,906,962

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Start Trial   Start Trial METHOD OF INCREASING HAIR GROWTH   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,906,962

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 309775   Start Trial
Australia 5303901   Start Trial
Canada 2401731   Start Trial
China 100384425   Start Trial
China 101229171   Start Trial
China 101897700   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Express Scripts
Baxter
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.